In particular, a recent study showed that the activation of LAG3 can resist the efficacy of anti-PD-1/B7-H1 therapy in tumor (16), and dual blockade of LAG3 and PD-1 can provoke more powerful antitumor or antiviral effects than the sum of blocking each molecule alone (12, 13, 15, 17–20). Here, PDCD1 is linked to neoplasm.